PL372941A1 - Sposoby terapeutyczne i zastosowanie sapogenin i ich pochodnych - Google Patents
Sposoby terapeutyczne i zastosowanie sapogenin i ich pochodnychInfo
- Publication number
- PL372941A1 PL372941A1 PL03372941A PL37294103A PL372941A1 PL 372941 A1 PL372941 A1 PL 372941A1 PL 03372941 A PL03372941 A PL 03372941A PL 37294103 A PL37294103 A PL 37294103A PL 372941 A1 PL372941 A1 PL 372941A1
- Authority
- PL
- Poland
- Prior art keywords
- derivatives
- sapogenins
- cognitive
- methods
- theraputic
- Prior art date
Links
- INLFWQCRAJUDCR-IQVMEADQSA-N (1R,2S,4S,5'S,6R,7S,8R,9S,12S,13S)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosane-6,2'-oxane] Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CCCCC4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@H](C)CO1 INLFWQCRAJUDCR-IQVMEADQSA-N 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title 1
- 230000001149 cognitive effect Effects 0.000 abstract 3
- 230000004770 neurodegeneration Effects 0.000 abstract 2
- 230000002232 neuromuscular Effects 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000006735 deficit Effects 0.000 abstract 1
- 230000007850 degeneration Effects 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 230000001537 neural effect Effects 0.000 abstract 1
- 230000003637 steroidlike Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Catalysts (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ARP020101170A AR033079A1 (es) | 2001-03-28 | 2002-03-27 | Derivados de sapogeninas, sintesis y uso, y metodos en base a su uso |
| US36817802P | 2002-03-28 | 2002-03-28 | |
| PCT/GB2002/001578 WO2002079221A2 (en) | 2001-03-28 | 2002-03-28 | Sapogenin derivatives, their synthesis and use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL372941A1 true PL372941A1 (pl) | 2005-08-08 |
| PL213697B1 PL213697B1 (pl) | 2013-04-30 |
Family
ID=30001210
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL372941A PL213697B1 (pl) | 2002-03-27 | 2003-03-27 | Substancje czynne do stosowania w leczeniu chorób, zwlaszcza chorób neurodegeneracyjnych |
Country Status (10)
| Country | Link |
|---|---|
| KR (1) | KR20100093621A (pl) |
| CN (1) | CN1642558B (pl) |
| AT (1) | ATE424211T1 (pl) |
| IL (1) | IL164161A0 (pl) |
| NZ (2) | NZ547897A (pl) |
| PE (1) | PE20040306A1 (pl) |
| PL (1) | PL213697B1 (pl) |
| RU (1) | RU2332999C2 (pl) |
| TW (1) | TWI329016B (pl) |
| WO (1) | WO2003082893A2 (pl) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6861788B2 (en) * | 2003-06-03 | 2005-03-01 | Motorola, Inc. | Switchable display/mirror method and apparatus |
| FR2868700B1 (fr) * | 2004-04-09 | 2008-09-26 | Michel Coisy | Utilisation de la dopamine ou de ses precurseurs biologiques contre l'algoneurodystrphie. |
| GB0409567D0 (en) | 2004-04-28 | 2004-06-02 | Phytopharm Plc | Chemical compounds |
| GB0424528D0 (en) * | 2004-11-05 | 2004-12-08 | Phytopharm Plc | Chemical compounds |
| PL1942920T3 (pl) * | 2005-10-28 | 2017-11-30 | University-Industry Cooperation Group Of Kyung Hee University | Ekstrakt z rodziny pochrzynowatych i kompozycja, która go zawiera dla zapobiegania lub leczenia nauropatii obwodowej |
| MX2011007842A (es) | 2009-01-24 | 2012-01-12 | Phytopharm Plc | Tratamiento de trastornos mediados por factores neurotroficos. |
| RU2402325C1 (ru) * | 2009-02-02 | 2010-10-27 | Государственное образовательное учреждение высшего профессионального образования "Волгоградский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" | Способ лечения нейрососудистых осложнений сахарного диабета |
| EP2595621A1 (en) * | 2010-07-20 | 2013-05-29 | Phytopharm PLC | Treatment of l-dopa, dopamine agonist and/or dopamine enhancer induced disorders |
| PT2753632T (pt) | 2011-09-08 | 2023-08-17 | Sage Therapeutics Inc | Esteróides neuroactivos, composições e respectivas utilizações |
| CU20110244A7 (es) * | 2011-12-27 | 2013-08-29 | Ct De Investigación Y Desarrollo De Medicamentos Cidem | Sistemas espiroesteroidales con efectos neuroactivos y anti-inflamatorios |
| US11319338B2 (en) | 2012-04-03 | 2022-05-03 | Goldporp Pharma Limited | Timosaponin compounds |
| SMT202500336T1 (it) | 2013-03-13 | 2025-11-10 | Sage Therapeutics Inc | Steroidi neuroattivi e loro metodi di utilizzo |
| CN103232520A (zh) * | 2013-05-13 | 2013-08-07 | 中国药科大学 | 一种螺甾类化合物、其制备方法及医药用途 |
| WO2015195967A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| AU2016289971C1 (en) | 2015-07-06 | 2022-12-08 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| JP6882996B2 (ja) | 2015-07-06 | 2021-06-02 | セージ セラピューティクス， インコーポレイテッド | オキシステロールおよびそれらの使用の方法 |
| CN113292623A (zh) | 2015-07-06 | 2021-08-24 | 萨奇治疗股份有限公司 | 孕甾醇及其使用方法 |
| JP7112331B2 (ja) | 2016-04-01 | 2022-08-03 | セージ セラピューティクス， インコーポレイテッド | オキシステロールおよびその使用方法 |
| US10752653B2 (en) | 2016-05-06 | 2020-08-25 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| TWI752976B (zh) | 2016-07-07 | 2022-01-21 | 美商賽吉醫療公司 | 氧固醇(oxysterol)及其使用方法 |
| CA3038900A1 (en) | 2016-09-30 | 2018-04-05 | Sage Therapeutics, Inc. | C7 substituted oxysterols and methods as nmda modulators |
| CN115322238A (zh) | 2016-10-18 | 2022-11-11 | 萨奇治疗股份有限公司 | 氧甾醇及其使用方法 |
| CN115181153A (zh) | 2016-10-18 | 2022-10-14 | 萨奇治疗股份有限公司 | 氧甾醇及其使用方法 |
| CN108264535A (zh) * | 2016-12-30 | 2018-07-10 | 中国科学院上海药物研究所 | 一种抗抑郁化合物及其制备方法和应用 |
| RU2635485C1 (ru) * | 2017-03-21 | 2017-11-13 | Федеральное государственное автономное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации | Способ лечения атрофии зрительного нерва после черепно-мозговой травмы |
| CN109988218B (zh) * | 2017-12-29 | 2022-11-25 | 中国科学院上海药物研究所 | 一种菝葜皂苷元衍生物及其制备方法和应用 |
| EP3572085A1 (en) * | 2018-05-25 | 2019-11-27 | Neuro-Sys | Synergestic combination composition comprising a steroidal saponin, a first polyphenolic compound and optionnaly a second polyphenolic compound |
| CN112457362B (zh) * | 2019-09-06 | 2023-09-19 | 上海青东生物科技有限公司 | 一种卤代四环三萜衍生物及其制备与应用 |
| US12454547B2 (en) | 2022-04-22 | 2025-10-28 | Asteroid Therapeutics | Steroidal compositions and methods of treating lipogenic cancers |
| CN118994294A (zh) * | 2024-08-08 | 2024-11-22 | 吉林农业大学 | 薤白中新甾体皂苷的分离鉴定及应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3416112A1 (de) * | 1984-04-30 | 1985-10-31 | Roecar Holdings (Netherlands Antilles) N.V., Willemstad, Curacao, Niederländische Antillen | Verwendung von sterolinen und spiroketalinen als lipoxygenaseregulatoren |
| US4680289A (en) * | 1985-06-05 | 1987-07-14 | Progenics, Inc. | Treatment of obesity and diabetes using sapogenins |
| JPH05246866A (ja) * | 1992-03-06 | 1993-09-24 | Ruibosuteii Japan:Kk | 脳代謝促進・脳機能改善剤 |
| DE4303214A1 (de) * | 1993-02-04 | 1994-08-11 | Wolfgang Marks | Behandlung von Erkrankungen viraler, viroidaler oder onkogener Genese durch Steroid-Saponine oder deren Aglykone |
| TW479061B (en) * | 1993-12-24 | 2002-03-11 | Mitsubishi Chem Corp | Sialic acid derivatives |
| JPH092956A (ja) * | 1995-06-22 | 1997-01-07 | Mitsubishi Chem Corp | 神経障害の治療、予防薬 |
| JPH092957A (ja) * | 1995-06-22 | 1997-01-07 | Mitsubishi Chem Corp | 末梢性神経障害の治療、予防薬 |
| US6046185A (en) * | 1996-07-11 | 2000-04-04 | Inflazyme Pharmaceuticals Ltd. | 6,7-oxygenated steroids and uses related thereto |
| CN1131237C (zh) * | 1997-09-26 | 2003-12-17 | 中国人民解放军军事医学科学院放射医学研究所 | 甾体皂甙防治老年性痴呆的用途及新的甾体皂甙 |
| GB9923076D0 (en) * | 1999-09-29 | 1999-12-01 | Phytopharm Plc | Sapogenin derivatives and their use |
| EP1066033B1 (en) * | 1998-03-26 | 2005-12-28 | Phytopharm Plc | Smilagenin and anzurogenin-d for the treatment of alzheimer's disease |
| GB9923078D0 (en) * | 1999-09-29 | 1999-12-01 | Phytopharm Plc | Sapogenin derivatives and their use |
| GB9923077D0 (en) * | 1999-09-29 | 1999-12-01 | Phytopharm Plc | Sapogenin derivatives and their use |
| GB0000228D0 (en) * | 2000-01-06 | 2000-03-01 | Phytopharm Plc | Fluoro substituted sapogenins and their use |
| JP2002030096A (ja) * | 2000-07-11 | 2002-01-29 | Kyorin Pharmaceut Co Ltd | 神経細胞突起再生剤及びその製造方法 |
| US20040072806A1 (en) * | 2002-03-15 | 2004-04-15 | Zhi-Xing Yao | Neuroprotective spirostenol pharmaceutical compositions |
-
2003
- 2003-03-27 PL PL372941A patent/PL213697B1/pl not_active IP Right Cessation
- 2003-03-27 NZ NZ547897A patent/NZ547897A/en unknown
- 2003-03-27 AT AT03722713T patent/ATE424211T1/de active
- 2003-03-27 WO PCT/GB2003/001380 patent/WO2003082893A2/en not_active Ceased
- 2003-03-27 KR KR1020107017081A patent/KR20100093621A/ko not_active Abandoned
- 2003-03-27 IL IL16416103A patent/IL164161A0/xx unknown
- 2003-03-27 RU RU2004130281/15A patent/RU2332999C2/ru not_active IP Right Cessation
- 2003-03-27 PE PE2003000315A patent/PE20040306A1/es not_active Application Discontinuation
- 2003-03-27 TW TW092106926A patent/TWI329016B/zh not_active IP Right Cessation
- 2003-03-27 CN CN038071886A patent/CN1642558B/zh not_active Expired - Fee Related
- 2003-03-27 NZ NZ547344A patent/NZ547344A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003082893A8 (en) | 2003-12-31 |
| CN1642558A (zh) | 2005-07-20 |
| PL213697B1 (pl) | 2013-04-30 |
| NZ547897A (en) | 2008-02-29 |
| WO2003082893A2 (en) | 2003-10-09 |
| IL164161A0 (en) | 2005-12-18 |
| TWI329016B (en) | 2010-08-21 |
| TW200400042A (en) | 2004-01-01 |
| KR20100093621A (ko) | 2010-08-25 |
| WO2003082893A3 (en) | 2004-04-15 |
| ATE424211T1 (de) | 2009-03-15 |
| PE20040306A1 (es) | 2004-05-29 |
| CN1642558B (zh) | 2012-05-30 |
| RU2004130281A (ru) | 2006-01-20 |
| RU2332999C2 (ru) | 2008-09-10 |
| NZ547344A (en) | 2007-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL372941A1 (pl) | Sposoby terapeutyczne i zastosowanie sapogenin i ich pochodnych | |
| WO2002079221A3 (en) | Sapogenin derivatives, their synthesis and use | |
| PT1246835E (pt) | Sapogeninas substituídas e sua utilização | |
| GB9923076D0 (en) | Sapogenin derivatives and their use | |
| PL343508A1 (en) | Smilagenin and anzurogenin-d and their use | |
| TW200528117A (en) | Methods and reagents for the treatment of proliferative diseases | |
| WO2003090695A3 (en) | TREATMENT OF α-GALACTOSIDASE A DEFICIENCY | |
| BG66289B1 (en) | Combination of epothilone analog and chemotherapeutic agents for the treatment of proliferative diseases | |
| CA2385410A1 (en) | Sapogenin derivatives and their use in the treatment of cognitive dysfunction | |
| WO2001079164A3 (en) | N-substituted dithiocarbamates for the treatment of biological disorders | |
| TW200640944A (en) | VGF polypeptides and methods of treating VGF-related disorders | |
| GB9923078D0 (en) | Sapogenin derivatives and their use | |
| WO2005000208A3 (en) | Combination therapy for the treatment of neoplasms | |
| MXPA02000680A (es) | Polipeptidos vgf y metodos para tratar desordenes relacionados con vgf. | |
| HRP20041009A2 (en) | Theraputic methods and uses of sapogenins and their derivatives | |
| WO2004105696A3 (en) | Combination therapy for the treatment of neoplasms | |
| IL171384A (en) | Use of slurp-1 in the preparation of medicaments for the treatment of neurological disorders | |
| TW200833344A (en) | Therapeutic methods and uses of sapogenins and their derivatives | |
| BR0308788A (pt) | Processos terapêuticos e usos de sapogeninas e seus derivados | |
| AU2003251734A1 (en) | Nicergoline, mmdl and mdl for the treatment of neurodegenerative disorders of the retina and optic nerve | |
| MY134920A (en) | 5-beta-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia | |
| WO2004073631A3 (en) | Combination therapy for the treatment of neoplasms | |
| AU2002951831A0 (en) | Underpants for the treatment of pelvic floor muscles and/or bladder | |
| WO2003052066A3 (en) | Klcs as modifiers of the p53 pathway and methods of use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| LAPS | Decisions on the lapse of the protection rights |
Effective date: 20130327 |